Addex Therapeutics Ltd




Biotechnology & Medical Research

Market Closed - Swiss Exchange 11:30:46 2024-06-19 am EDT 5-day change 1st Jan Change
0.062 CHF -4.62% Intraday chart for Addex Therapeutics Ltd 0.00% +34.78%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Addex Therapeutics Ltd, Q1 2024 Earnings Call, Jun 06, 2024
Addex Therapeutics' Q1 Net Loss Widens; Revenue Down MT
Addex to Present at BioEURquity Europe 2024 DJ
European Equities Traded in the US as American Depositary Receipts Decline MT
Sector Update: Health Care Stocks Edge Higher Late Afternoon MT
Sector Update: Health Care MT
Top Midday Decliners MT
Addex Therapeutics Shares Plunge as Phase 2 Study of ADX71149 Falls Short of Primary Goal MT
Tech Rally Subsides as US Equity Futures Waver Pre-Bell MT
Top Premarket Decliners MT
Addex Therapeutics Shares Plunge Premarket on Epilepsy Study Failure DJ
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study CI
Top Premarket Decliners MT
Transcript : Addex Therapeutics Ltd, 2023 Earnings Call, Apr 18, 2024
Addex Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Addex Therapeutics Logs Decline in FY23 Net Loss; Revenue Rises MT
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update DJ
ADRs End Higher; Biophytis Climbs 30% DJ
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data MT
Top Premarket Gainers MT
ADRs Advance, Eco Wave Power Global AB Climbs 213.4% DJ
Powell Speech Eyed, Intel Weighs on Sentiment as US Equity Futures Waver Premarket MT
Top Premarket Gainers MT
Addex Therapeutics Announces the Launch of Neurosterix, Company Focused on Developing Allosteric Modulators for the Treatment of Underserved Neurological Disorders CI
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders DJ
Chart Addex Therapeutics Ltd
More charts
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
0.065 CHF
Average target price
0.16 CHF
Spread / Average Target